Regulation
Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval
Lantheus Holdings received FDA approval for a radiodiagnostic agent designed to identify cognitive impairment associated with tau neurofibrillary tangle pathology in Alzheimer's disease. The diagnostic imaging agent enables visualization and detection of tau pathology in patients with cognitive decline.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network